Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent LeasesFinished GoodsInventoryLiabilities and Shareholders EquityNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Raw MaterialsReceivablesRetained EarningsShareholder's EquityShares OutstandingShort term DebtShort-term InvestmentsTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesWork In Process
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Karyopharm Therapeutics (KPTI) Current Deferred Revenue (2016 - 2020)

Karyopharm Therapeutics' Current Deferred Revenue history spans 9 years, with the latest figure at $297000.0 for Q4 2020.

  • For Q4 2020, Current Deferred Revenue fell 93.45% year-over-year to $297000.0; the TTM value through Dec 2020 reached $297000.0, down 93.45%, while the annual FY2020 figure was $297000.0, 93.45% down from the prior year.
  • Current Deferred Revenue reached $297000.0 in Q4 2020 per KPTI's latest filing, roughly flat from $297000.0 in the prior quarter.
  • In the past five years, Current Deferred Revenue ranged from a high of $10.6 million in Q1 2019 to a low of $178000.0 in Q1 2018.
  • Average Current Deferred Revenue over 5 years is $1.7 million, with a median of $297000.0 recorded in 2020.
  • Peak YoY movement for Current Deferred Revenue: surged 5883.15% in 2019, then plummeted 93.45% in 2020.
  • A 5-year view of Current Deferred Revenue shows it stood at $280000.0 in 2016, then rose by 8.21% to $303000.0 in 2017, then surged by 2989.77% to $9.4 million in 2018, then crashed by 51.58% to $4.5 million in 2019, then tumbled by 93.45% to $297000.0 in 2020.
  • Per Business Quant, the three most recent readings for KPTI's Current Deferred Revenue are $297000.0 (Q4 2020), $297000.0 (Q3 2020), and $297000.0 (Q2 2020).